Monthly Archives: May 2017

19 May 2017

Horizon Discovery – Parkwalk UCEF I exit

By |May 19th, 2017|

We are delighted to have generated a 2.36x return (3.37x inclusive of initial tax reliefs) for our investors on the sale of the University of Cambridge Enterprise Fund I holding in Horizon Discovery plc. The investment was held for 3.9 years and the exit was generated through a single block trade.
We would like to thank […]

Predictimmune – Parkwalk closes investment

By |May 16th, 2017|

We are delighted to announce that the Parkwalk Opportunities Fund and the University of Cambridge Enterprise Fund IV have completed an investment in Predictimmune Limited, a spinout company from the University of Cambridge.
Predictimmune is developing prognostic tests for immune-mediated conditions to aid their management and improve patient outcomes. Their first offering, PredictImmune-CD, will be […]

Brainomix joins forces with Boehringer Ingelheim to help save stroke victims

By |May 9th, 2017|

Oxford – An ambitious collaboration between Brainomix, an emerging British business, and Boehringer Ingelheim, one of the world’s largest drug companies, is poised to expedite and improve treatment of stroke, the second biggest killer disease in Europe.

The Brainomix team has pioneered the rapid digital analysis of scans of patients admitted to hospital with stroke. […]